{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:13:27Z","timestamp":1778714007515,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Labex TRAIL","award":["ANR-10-LABEX-57"],"award-info":[{"award-number":["ANR-10-LABEX-57"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-39705-y","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:58:10Z","timestamp":1774533490000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bevacizumab-IRDye800 as an imaging probe for the detection of prostate cancer in mice"],"prefix":"10.1038","volume":"16","author":[{"given":"Coralie","family":"Genevois","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Dugot-Senant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Helene","family":"Canron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamia","family":"Azzi-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Grenier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Couillaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Mazzocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"39705_CR1","doi-asserted-by":"publisher","unstructured":"Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA: a cancer journal for clinicians 62, 10\u201329. (2012). https:\/\/doi.org\/10.3322\/caac.20138","DOI":"10.3322\/caac.20138"},{"key":"39705_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00345-012-0824-2","volume":"30","author":"OW Brawley","year":"2012","unstructured":"Brawley, O. W. Prostate cancer epidemiology in the United States. World J. Urol. 30, 195\u2013200. https:\/\/doi.org\/10.1007\/s00345-012-0824-2 (2012).","journal-title":"World J. Urol."},{"key":"39705_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","volume":"157","author":"VA Moyer","year":"2012","unstructured":"Moyer, V. A. Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann. Intern. Med. 157, 120\u2013134. https:\/\/doi.org\/10.7326\/0003-4819-157-2-201207170-00459 (2012).","journal-title":"Ann. Intern. Med."},{"key":"39705_CR4","doi-asserted-by":"crossref","unstructured":"Braunhut, B. L., Punnen, S. & Kryvenko, O. N. Updates on grading and staging of prostate cancer. Surg. Pathol. Clin. (2018).","DOI":"10.1016\/j.path.2018.07.003"},{"key":"39705_CR5","unstructured":"Cornford, P. et al. Guidelines on prostate Cancer-2024 Update. Part I: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 86, 148\u2013163 (2024)."},{"key":"39705_CR6","unstructured":"Silver, D.A., Pellicer I Fau - Fair, W.R., Fair Wr Fau - Heston, W.D., Heston Wd Fau - Cordon-Cardo, C., & Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. (1997)."},{"key":"39705_CR7","unstructured":"Israeli, R.S., Powell Ct Fau - Corr, J.G., Corr Jg Fau - Fair, W.R., Fair Wr Fau - Heston, W.D., & Heston, W.D. Expression of the prostate-specific membrane antigen. Cancer Res. (1994)."},{"key":"39705_CR8","doi-asserted-by":"crossref","unstructured":"Troyer, J.K., Beckett Ml Fau - Wright, G.L., Jr., & Wright, G.L., Jr. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 30(4), 232\u2013242 (1997).","DOI":"10.1002\/(SICI)1097-0045(19970301)30:4<232::AID-PROS2>3.0.CO;2-N"},{"key":"39705_CR9","doi-asserted-by":"crossref","unstructured":"Bander, N. H. Technology insight: monoclonal antibody imaging of prostate cancer. Nat. Clin. Pract. (4), 216\u2013225 (2006).","DOI":"10.1038\/ncpuro0452"},{"key":"39705_CR10","doi-asserted-by":"crossref","unstructured":"Dietlein, M. et al. Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol. Imaging Biol. (2015).","DOI":"10.1007\/s11307-015-0866-0"},{"key":"39705_CR11","doi-asserted-by":"publisher","first-page":"995","DOI":"10.2967\/jnumed.114.138180","volume":"55","author":"S L\u00fctje","year":"2014","unstructured":"L\u00fctje, S. et al. Dual-modality image-guided surgery of prostate cancer with a radiolabeled fluorescent anti-PSMA monoclonal antibody. J. Nucl. Med. 55, 995. https:\/\/doi.org\/10.2967\/jnumed.114.138180 (2014).","journal-title":"J. Nucl. Med."},{"key":"39705_CR12","doi-asserted-by":"crossref","unstructured":"Afshar-Oromieh, A. et al. The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging (2), 197\u2013209 (2015).","DOI":"10.1007\/s00259-014-2949-6"},{"key":"39705_CR13","doi-asserted-by":"crossref","unstructured":"Eiber, M. et al. (68)Ga-PSMA PET\/MR with multimodality image analysis for primary prostate cancer. Abdom Imaging (6), 1769\u20131771 (2015).","DOI":"10.1007\/s00261-014-0301-z"},{"key":"39705_CR14","doi-asserted-by":"crossref","unstructured":"Dassie, J. P. et al. Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen. Mol. Ther. (11), 1910\u20131922 (2014).","DOI":"10.1038\/mt.2014.117"},{"key":"39705_CR15","doi-asserted-by":"publisher","unstructured":"Chen, Y. A. O. et al. Synthesis, preclinical evaluation, and first-in-human assessment of ICG-PSMA-D5: a PSMA-targeted probe for fluorescence-guided surgery of prostate cancer. J. Med. Chem. 68(3), 3858\u20133872. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02989 (2025).","DOI":"10.1021\/acs.jmedchem.4c02989"},{"key":"39705_CR16","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1007\/s00259-023-06492-x","volume":"51","author":"H Fu","year":"2024","unstructured":"Fu, H. et al. A novel PSMA targeted dual-function near-infrared fluorescence and PET probe for the image-guided surgery and detection of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 51, 2998\u20133008. https:\/\/doi.org\/10.1007\/s00259-023-06492-x (2024).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"39705_CR17","doi-asserted-by":"crossref","unstructured":"Miller, S. E. et al. First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800. J. Neurooncol. (1), 135\u2013143 (2018).","DOI":"10.1007\/s11060-018-2854-0"},{"key":"39705_CR18","doi-asserted-by":"crossref","unstructured":"Rosenthal, E. L. et al. Safety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancer. Clin. Cancer. 15(16), 3658\u20133666 (2015).","DOI":"10.1158\/1078-0432.CCR-14-3284"},{"key":"39705_CR19","doi-asserted-by":"crossref","unstructured":"Lamberts, L. E. et al. Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study. Clin. Cancer 1(11), 2730\u20132741 (2017).","DOI":"10.1158\/1078-0432.CCR-16-0437"},{"issue":"1","key":"39705_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/gutjnl-2017-314953","volume":"68","author":"WB Nagengast","year":"2019","unstructured":"Nagengast, W. B. et al. Near-infrared fluorescence molecular endoscopy detects dysplastic oesophageal lesions using topical and systemic tracer of vascular endothelial growth factor A. Gut 68 (1), 7\u201310 (2019).","journal-title":"Gut"},{"issue":"6","key":"39705_CR21","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.7150\/thno.22033","volume":"8","author":"E Hartmans","year":"2018","unstructured":"Hartmans, E. et al. Potential red-flag identification of colorectal adenomas with wide-field fluorescence molecular endoscopy. Theranostics 8 (6), 1458\u20131467 (2018).","journal-title":"Theranostics"},{"key":"39705_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S2468-1253(16)30082-6","volume":"1","author":"NJ Harlaar","year":"2016","unstructured":"Harlaar, N. J. et al. Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study. Lancet Gastroenterol. Hepatol. 1, 283\u2013290. https:\/\/doi.org\/10.1016\/S2468-1253(16)30082-6 (2016).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"39705_CR23","doi-asserted-by":"crossref","unstructured":"Ferrer, F. A., et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J. Urol. (6), 2323\u20132328 (1997).","DOI":"10.1016\/S0022-5347(01)64774-8"},{"key":"39705_CR24","doi-asserted-by":"crossref","unstructured":"Wong, S. Y. et al. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res. (21), 9789\u20139798 (2005).","DOI":"10.1158\/0008-5472.CAN-05-0901"},{"key":"39705_CR25","doi-asserted-by":"publisher","unstructured":"Josserand, V. et al. Tumor-specific imaging with angiostamp800 or bevacizumab-IRDye 800CW improves fluorescence-guided surgery over indocyanine green in peritoneal carcinomatosis. Biomedicines 10, 1059. (2022). https:\/\/doi.org\/10.3390\/biomedicines10051059","DOI":"10.3390\/biomedicines10051059"},{"key":"39705_CR26","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.7150\/thno.24487","volume":"8","author":"RW Gao","year":"2018","unstructured":"Gao, R. W. et al. Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers. Theranostics 8, 2488\u20132495. https:\/\/doi.org\/10.7150\/thno.24487 (2018).","journal-title":"Theranostics"},{"key":"39705_CR27","doi-asserted-by":"crossref","unstructured":"Hrouda, D., Nicol Dl Fau - Gardiner, R.A. & Gardiner, R.A. The role of angiogenesis in prostate development and the pathogenesis of prostate cancer. Urol. Res.(6), 347\u2013355 (2003).","DOI":"10.1007\/s00240-002-0287-9"},{"key":"39705_CR28","doi-asserted-by":"crossref","unstructured":"Desmettre, T., Mordon, D. J. F. & Mordon, S. S. Fluorescence properties and metabolic features of indocyanine green (ICG) as related to angiography. Surv. Ophthalmol. 45(1), 15\u201327 (2000).","DOI":"10.1016\/S0039-6257(00)00123-5"},{"key":"39705_CR29","unstructured":"Kaighn Me Fau - Narayan, K.S., Narayan Ks Fau - Ohnuki, Y., Ohnuki Y Fau - Lechner, J.F., Lechner Jf Fau - Jones, L.W. & Jones, L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. (1), 16\u201323 (1979)."},{"key":"39705_CR30","unstructured":"Mickey, D. F. et al. Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. Cancer Res. 37(11), 4049\u20134058 (1977)."},{"key":"39705_CR31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","volume":"7","author":"Y Wang","year":"2004","unstructured":"Wang, Y., Fei, D., Vanderlaan, M. & Song, A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7, 335\u2013345. https:\/\/doi.org\/10.1007\/s10456-004-8272-2 (2004).","journal-title":"Angiogenesis"},{"key":"39705_CR32","doi-asserted-by":"crossref","unstructured":"Mazzocco, C. et al. In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe. Sci. Rep. 6, 23314 (2016).","DOI":"10.1038\/srep23314"},{"key":"39705_CR33","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1021\/bc2002715","volume":"22","author":"T Nakajima","year":"2011","unstructured":"Nakajima, T. et al. Targeted, Activatable, in vivo fluorescence imaging of Prostate-Specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody\u2013indocyanine green (ICG) conjugate. Bioconjug. Chem. 22, 1700\u20131705. https:\/\/doi.org\/10.1021\/bc2002715 (2011).","journal-title":"Bioconjug. Chem."},{"key":"39705_CR34","doi-asserted-by":"crossref","unstructured":"Tsai, W. K. et al. Dual-modality immunoPET\/fluorescence imaging of prostate cancer with an anti-PSCA Cys-minibody. Theranostics (21), 5903\u20135914 (2018).","DOI":"10.7150\/thno.27679"},{"key":"39705_CR35","doi-asserted-by":"crossref","unstructured":"Rashidian, M. et al. Noninvasive imaging of immune responses. Proc. Natl. Acad. Sci. USA. 12(19), 6146\u20136151 (2015).","DOI":"10.1073\/pnas.1502609112"},{"key":"39705_CR36","doi-asserted-by":"crossref","unstructured":"Zhang, M. et al. Near-infrared dye-labeled anti-prostate stem cell antigen minibody enables real-time fluorescence imaging and targeted surgery in translational mouse models. Clin. Cancer 1(1), 188\u2013200 (2019).","DOI":"10.1158\/1078-0432.CCR-18-1382"},{"key":"39705_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.euo.2023.07.004","volume":"7","author":"HG Nguyen","year":"2024","unstructured":"Nguyen, H. G. et al. First-in-human evaluation of a prostate-specific membrane antigen\u2013targeted near-infrared fluorescent small molecule for fluorescence-based identification of prostate cancer in patients with high-risk prostate cancer undergoing robotic-assisted prostatectomy. Eur. Urol. Oncol. 7, 63\u201372. https:\/\/doi.org\/10.1016\/j.euo.2023.07.004 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"39705_CR38","doi-asserted-by":"crossref","unstructured":"Tian, Y. et al. Enhancing surgical outcomes: accurate identification and removal of prostate cancer with B7-H3-targeted NIR-II molecular imaging. Eur. J. Nucl Med. Mol. Imaging (9), 2569\u20132582 (2024).","DOI":"10.1007\/s00259-024-06714-w"},{"key":"39705_CR39","doi-asserted-by":"publisher","first-page":"064001","DOI":"10.1117\/1.3257236","volume":"14","author":"B Jerome","year":"2009","unstructured":"Jerome, B. et al. Bimodal ultrasound and fluorescence approach for prostate cancer diagnosis. J. Biomed. Opt. 14, 064001. https:\/\/doi.org\/10.1117\/1.3257236 (2009).","journal-title":"J. Biomed. Opt."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39705-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39705-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39705-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:58:23Z","timestamp":1778713103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39705-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["39705"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-39705-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study is reported in accordance with ARRIVE guidelines (\n                      \n                      ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"15108"}}